BG107856A - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - Google Patents

Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Info

Publication number: BG107856A
Authority: BG; Bulgaria
Prior art keywords: processes; forms; novel; preparation; preparing
Prior art date: 2000-11-30

Application number

BG107856A

Other languages

Bulgarian (bg)

English (en)

Inventor

Judith Aronhime

Rami Lidor-Hadas

Valerie Niddam-Hildesheim

Revital Lifshitz-Liron

Eti Kovalesvski-Ishai

Guy Samburski

Original Assignee

Teva Pharmaceutical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-30

Filing date

2003-05-29

Publication date

2004-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27540285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107856(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-29 Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd

2004-11-30 Publication of BG107856A publication Critical patent/BG107856A/xx

Links

FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 1
239000013078 crystal Substances 0.000 title 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 3
229960005370 atorvastatin Drugs 0.000 abstract 3

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG107856A 2000-11-30 2003-05-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms BG107856A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date
US25007200P	2000-11-30	2000-11-30
US26789701P	2001-02-09	2001-02-09
US28187201P	2001-04-05	2001-04-05
US31214401P	2001-08-13	2001-08-13
US32652901P	2001-10-01	2001-10-01

Publications (1)

Publication Number	Publication Date
BG107856A true BG107856A (en)	2004-11-30

Family

ID=27540285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107856A BG107856A (en)	2000-11-30	2003-05-29	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Country Status (23)

Country	Link
US (15)	US20020183378A1 (fr)
EP (5)	EP2192113A1 (fr)
JP (2)	JP2004514694A (fr)
KR (1)	KR100765871B1 (fr)
CN (1)	CN1489463A (fr)
AU (1)	AU2002217927A1 (fr)
BG (1)	BG107856A (fr)
BR (1)	BR0115892A (fr)
CA (3)	CA2625277A1 (fr)
CZ (1)	CZ20031766A3 (fr)
DE (1)	DE01998348T1 (fr)
ES (2)	ES2215495T1 (fr)
HR (2)	HRP20030523A2 (fr)
HU (1)	HUP0600538A3 (fr)
IL (2)	IL156055A0 (fr)
IS (1)	IS6829A (fr)
MX (1)	MXPA03004844A (fr)
NO (1)	NO20032425L (fr)
PL (1)	PL363228A1 (fr)
SK (1)	SK8062003A3 (fr)
TR (1)	TR200400815T3 (fr)
WO (1)	WO2002043732A1 (fr)
YU (1)	YU42803A (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE36268E (en) *	1988-03-15	1999-08-17	Boehringer Mannheim Corporation	Method and apparatus for amperometric diagnostic analysis
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
CZ20031495A3 (cs) *	2000-11-03	2004-01-14	Teva Pharmaceutical Industries Ltd.	Forma VII hemi-kalcium atorvastatinu
HUP0303555A3 (en) *	2000-11-16	2005-08-29	Teva Pharma	Hydrolysis of [r(r
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) *	2000-12-27	2007-04-05	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
SK16002003A3 (sk)	2001-06-29	2004-12-01	Warner-Lambert Company Llc	Kryštalické formy vápenatej soli (2:1) [R-(R,R)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
RU2304139C2 (ru) *	2001-07-30	2007-08-10	Д-р Редди'с Лабораторис Лтд	Кристаллические формы vi и vii кальциевой соли аторвастатина
HUP0500616A3 (en) *	2001-08-16	2011-07-28	Teva Pharma	Processes for preparing calcium salt forms of statins
CZ296967B6 (cs) *	2002-02-01	2006-08-16	Zentiva, A.S.	Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
MXPA04007939A (es) *	2002-02-15	2004-11-26	Teva Pharma	Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix.
MXPA04007995A (es)	2002-02-19	2004-11-26	Teva Pharma	Desolvatacion de solvatos de hemicalcio de atorvastatina.
AU2002356423A1 (en) *	2002-05-28	2003-12-12	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
US20060122403A1 (en) *	2002-09-03	2006-06-08	Sanjay Suri	Atorvastatin calcium form vi or hydrates thereof
EP1572643A2 (fr) *	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Forme cristalline du sel hemi calcique de l'atorvastatine
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
CN1812983A (zh)	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
US7790197B2 (en)	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
ITMI20032144A1 (it) *	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
CA2456430A1 (fr) *	2004-01-28	2005-07-28	Brantford Chemicals Inc.	Procede ameliore pour la preparation d'atorvastatine calcique amorphe
AU2004317570B2 (en)	2004-03-17	2011-01-06	Ranbaxy Laboratories Limited	Process for the production of atorvastatin calcium in amorphous form
US7875731B2 (en)	2004-05-05	2011-01-25	Pfizer Inc.	Salt forms of [R-(R,R)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
EP1773769A1 (fr) *	2004-05-24	2007-04-18	Warner-Lambert Company LLC	Formes salines d'atorvastatine
AU2005263550C1 (en) *	2004-07-16	2013-01-17	Lek Pharmaceuticals D.D.	Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) *	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
JP2007505944A (ja) *	2004-07-22	2007-03-15	テバファーマシューティカルインダストリーズリミティド	アトルバスタチンヘミカルシウム及びその調製の方法
US7674923B2 (en) *	2004-09-28	2010-03-09	Teva Pharmaceutical Industries Ltd	Process for preparing forms of atorvastatin calcium substantially free of impurities
CA2582449A1 (fr) *	2004-09-30	2006-04-13	Dr. Reddy's Laboratories Ltd.	Atorvastatine calcique amorphe
KR20070054730A (ko) *	2004-10-18	2007-05-29	테바 파마슈티컬 인더스트리즈 리미티드	알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
CA2585836A1 (fr)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Procede de formation d'atorvastatine amorphe
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
WO2006054308A2 (fr) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Formulations d'atorvastatine stables
SI1698630T1 (sl) *	2005-03-03	2015-01-30	Alfa Wassermann S.P.A.	Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
WO2006106372A1 (fr) *	2005-04-08	2006-10-12	EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság	Nouvelle forme polymorphe de sel d'hemicalcium d'atorvastatine cristallin
US20070032665A1 (en) *	2005-08-04	2007-02-08	Srinivasulu Gudipati	Preparation of atorvastatin calcium form i
ES2270722B1 (es) *	2005-09-15	2008-03-01	Ercros Industrial, S.A.	Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) *	2005-09-16	2009-08-27	Yatendra Kumar	Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr) *	2005-09-21	2007-03-21	Renuka D. Reddy	Procede de recuit de l'atorvastatine amorphe
SG166829A1 (en)	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
EP1923057A1 (fr)	2005-11-21	2008-05-21	Teva Pharmaceutical Industries Ltd	Formule pharmaceutique atorvastanine
WO2007057755A1 (fr)	2005-11-21	2007-05-24	Warner-Lambert Company Llc	Nouvelles formes d’acide [r-(r,r)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique magnesium
EP1808162A1 (fr)	2005-11-21	2007-07-18	Teva Pharmaceutical Industries Ltd.	Formulation pharmacéutique de l'Atorvastatin
CA2633268A1 (fr) *	2005-12-13	2007-06-21	Teva Pharmaceutical Industries Ltd.	Forme cristalline d'hemi-calcium d'atorvastatine et procedes de fabrication de celle-ci
EP1810667A1 (fr)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique contenant de l'atorvastatin amorphé
JP2007246514A (ja) *	2006-02-14	2007-09-27	Toyama Chem Co Ltd	ピペラシリンナトリウムの新規な結晶
WO2007096903A2 (fr) *	2006-02-22	2007-08-30	Matrix Laboratories Ltd	Nouvelle forme cristalline d'hemi-calcium d'atorvastatine
CA2640573A1 (fr) *	2006-03-01	2007-09-13	Michael Pinchasov	Procede de preparation d'une forme cristalline d'hemi-calcium d'atorvastatine
US20070265456A1 (en) *	2006-05-09	2007-11-15	Judith Aronhime	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) *	2006-06-30	2008-07-30	浙江新东港药业股份有限公司	一种无定型阿伐他汀钙的制备方法
WO2008010087A2 (fr) *	2006-07-14	2008-01-24	Ranbaxy Laboratories Limited	FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
US20100029743A1 (en) *	2006-09-27	2010-02-04	Dr. Reddy's Laboratories Ltd.	Atorvastatin pharmaceutical compositions
WO2008053312A2 (fr) *	2006-11-02	2008-05-08	Cadila Pharmaceuticals Limited	Procédé de préparation d'un sel d'hémicalcium d'atorvastatine amorphe et intermédiaire de ce dernier
US7834195B2 (en) *	2007-01-24	2010-11-16	Apotex Pharmachem Inc.	Atorvastatin calcium propylene glycol solvates
MX2009008124A (es) *	2007-01-31	2009-10-08	Toyama Chemical Co Ltd	Cristal nuevo de piperacilina sodica.
EP2132171A4 (fr) *	2007-03-02	2010-11-17	Dong A Pharm Co Ltd	Nouvelles formes cristallines de dérivés d'acide pyrrolylheptanoïque
WO2008129562A2 (fr) *	2007-04-20	2008-10-30	Morepen Laboratories Limited	Procédé amélioré pour la préparation d'atorvastatine amorphe hémicalcique stable et de ses sels
JP2010534644A (ja) *	2007-07-27	2010-11-11	シプラ・リミテッド	医薬組成物およびその製造方法
WO2009082362A1 (fr) *	2007-11-05	2009-07-02	Ulkar Kimya San. Ve Tic. A.S.	Procédé de procution de statines sous forme pure
EP2075246A1 (fr)	2007-12-27	2009-07-01	M. J. Institute of Research	Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
CN101538237B (zh) *	2008-05-30	2011-04-06	天津和美生物技术有限公司	阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
US8685173B2 (en)	2008-07-17	2014-04-01	Delaval Holding Ab	Method of cleaning food and beverage manufacturing and handling equipment
US9334266B2 (en)	2009-09-04	2016-05-10	The University Of Toledo	Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
US11473032B2 (en)	2010-02-02	2022-10-18	Fuchs Petrolub Se	Constant velocity joint having a boot
IT1398550B1 (it)	2010-03-05	2013-03-01	Alfa Wassermann Spa	Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN102766136A (zh) *	2012-08-07	2012-11-07	浙江宏元药业有限公司	一种制备阿托伐他汀钙中间体的方法
EP3578546A1 (fr)	2013-11-15	2019-12-11	Akebia Therapeutics Inc.	Formes solides d'acide acétique {[5-(3-chlorophényl) -3-hydroxypyridine-2-carbonyl] amino}, compositions et leurs utilisations
CN105111123A (zh) *	2013-11-25	2015-12-02	李兴惠	阿托伐他汀钙及组合物
CN104945300B (zh) *	2015-06-17	2017-05-10	北京嘉林药业股份有限公司	一种ⅰ型阿托伐他汀钙的纯化方法
CN104983690A (zh) *	2015-08-18	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
EP3272336A1 (fr) *	2016-07-19	2018-01-24	Stada Arzneimittel Ag	Composition d'atorvastatine
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US99224A (en) *		1870-01-25		Improvement in pocket-sates for friction-matches
US115709A (en) *		1871-06-06		Improvement in curriers slickers
US2598627A (en) *	1949-10-11	1952-05-27	Robert Gair Co Inc	Folding carton
US4137322A (en) *	1976-11-02	1979-01-30	Sankyo Company Limited	ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
US4681893A (en) *	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) *	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3254219B2 (ja) *	1993-01-19	2002-02-04	ワーナー−ランバート・コンパニー	安定な経口用のｃｉ−９８１製剤およびその製法
US5298627A (en) *	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (de) *	1994-04-02	1995-10-05	Cassella Ag	Wasserquellbare hydrophile Polymere
KR100431038B1 (ko)	1995-07-17	2004-05-12	워너-램버트 캄파니 엘엘씨	결정질[ｒ-(ｒ,ｒ)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
HRP960313B1 (en) *	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en)	1996-07-16	2000-07-11	Warner-Lambert Company	Process for the production of amorphous [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6065729A (en) *	1998-01-28	2000-05-23	Prince Corporation	Slide-out container holder
US5959156A (en)	1998-11-12	1999-09-28	Bp Amoco Corporation	Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (fr) *	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
HU226640B1 (en) *	1999-10-18	2009-05-28	Egis Gyogyszergyar Nyilvanosan	Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) *	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
CZ20021642A3 (cs) *	1999-11-17	2003-05-14	Teva Pharmaceutical Industries Ltd.	Polymorfní formy atorvastatinu vápenatého
SI20425A (sl) *	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
WO2001044181A1 (fr) *	1999-12-17	2001-06-21	Warner Lambert Research And Development Ireland Limited	Procede pour produire de l'atorvastatine calcique cristallin
EP1237865B1 (fr)	1999-12-17	2005-11-16	Pfizer Science and Technology Ireland Limited	Procede de production a l'echelle industrielle de sel d'hemi-calcium trihydrate d'atorvastatine cristallise
CZ20031495A3 (cs) *	2000-11-03	2004-01-14	Teva Pharmaceutical Industries Ltd.	Forma VII hemi-kalcium atorvastatinu
HUP0303555A3 (en) *	2000-11-16	2005-08-29	Teva Pharma	Hydrolysis of [r(r
US7501450B2 (en) *	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) *	2000-12-27	2007-04-05	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
US6476235B2 (en)	2001-01-09	2002-11-05	Warner-Lambert Company	Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (fr)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatine calcique
WO2002057229A1 (fr)	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl) *	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fr)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
SK16002003A3 (sk) *	2001-06-29	2004-12-01	Warner-Lambert Company Llc	Kryštalické formy vápenatej soli (2:1) [R-(R,R)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
US7074818B2 (en) *	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
RU2304139C2 (ru)	2001-07-30	2007-08-10	Д-р Редди'с Лабораторис Лтд	Кристаллические формы vi и vii кальциевой соли аторвастатина
HUP0500616A3 (en) *	2001-08-16	2011-07-28	Teva Pharma	Processes for preparing calcium salt forms of statins
WO2003018547A2 (fr)	2001-08-31	2003-03-06	Morepen Laboratories Ltd.	Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
WO2004009759A2 (fr)	2001-11-30	2004-01-29	University Of Maryland, Baltimore	Nouvelles proteines dans escherichia coli entero-agregatif (eaec) utilisees pour le diagnostic et la therapie d'infections a eaec
UA77990C2 (en) *	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
MXPA04007939A (es)	2002-02-15	2004-11-26	Teva Pharma	Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix.
MXPA04007995A (es)	2002-02-19	2004-11-26	Teva Pharma	Desolvatacion de solvatos de hemicalcio de atorvastatina.
EP1488315A2 (fr)	2002-03-28	2004-12-22	Emc Corporation	Systeme de stockage de donnees
AU2002356423A1 (en) *	2002-05-28	2003-12-12	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
US20060122403A1 (en) *	2002-09-03	2006-06-08	Sanjay Suri	Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl)	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
EP1424324A1 (fr)	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
EP1572643A2 (fr)	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Forme cristalline du sel hemi calcique de l'atorvastatine
US20040242670A1 (en) *	2003-06-02	2004-12-02	Sonny Sebastian	Process for preparation of amorphous atorvastatin calcium
JP2007505944A (ja) *	2004-07-22	2007-03-15	テバファーマシューティカルインダストリーズリミティド	アトルバスタチンヘミカルシウム及びその調製の方法
KR20070054730A (ko) *	2004-10-18	2007-05-29	테바 파마슈티컬 인더스트리즈 리미티드	알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
US20070032665A1 (en) *	2005-08-04	2007-02-08	Srinivasulu Gudipati	Preparation of atorvastatin calcium form i

2001
- 2001-10-29 IL IL15605501A patent/IL156055A0/xx unknown
- 2001-11-29 YU YU42803A patent/YU42803A/sh unknown
- 2001-11-29 CA CA002625277A patent/CA2625277A1/fr not_active Abandoned
- 2001-11-29 PL PL01363228A patent/PL363228A1/xx not_active Application Discontinuation
- 2001-11-29 MX MXPA03004844A patent/MXPA03004844A/es active IP Right Grant
- 2001-11-29 TR TR2004/00815T patent/TR200400815T3/xx unknown
- 2001-11-29 KR KR1020037007298A patent/KR100765871B1/ko not_active Expired - Fee Related
- 2001-11-29 ES ES01998348T patent/ES2215495T1/es active Pending
- 2001-11-29 AU AU2002217927A patent/AU2002217927A1/en not_active Abandoned
- 2001-11-29 CN CNA018223400A patent/CN1489463A/zh active Pending
- 2001-11-29 EP EP10152443A patent/EP2192113A1/fr not_active Withdrawn
- 2001-11-29 EP EP06024449A patent/EP1783113A3/fr not_active Ceased
- 2001-11-29 WO PCT/US2001/044636 patent/WO2002043732A1/fr not_active Ceased
- 2001-11-29 CA CA002429590A patent/CA2429590C/fr not_active Expired - Fee Related
- 2001-11-29 EP EP01998348A patent/EP1363621A4/fr not_active Ceased
- 2001-11-29 EP EP10151205.1A patent/EP2192112B1/fr not_active Expired - Lifetime
- 2001-11-29 ES ES10151205.1T patent/ES2437157T3/es not_active Expired - Lifetime
- 2001-11-29 EP EP10151206A patent/EP2194041A1/fr not_active Withdrawn
- 2001-11-29 HU HU0600538A patent/HUP0600538A3/hu unknown
- 2001-11-29 DE DE0001363621T patent/DE01998348T1/de active Pending
- 2001-11-29 CA CA2689915A patent/CA2689915A1/fr not_active Abandoned
- 2001-11-29 HR HR20030523A patent/HRP20030523A2/hr not_active Application Discontinuation
- 2001-11-29 BR BR0115892-9A patent/BR0115892A/pt not_active IP Right Cessation
- 2001-11-29 CZ CZ20031766A patent/CZ20031766A3/cs unknown
- 2001-11-29 JP JP2002545702A patent/JP2004514694A/ja active Pending
- 2001-11-29 SK SK806-2003A patent/SK8062003A3/sk unknown
- 2001-11-29 US US09/997,126 patent/US20020183378A1/en not_active Abandoned
- 2001-11-29 HR HRP20130545AA patent/HRP20130545A2/hr not_active Application Discontinuation
2003
- 2003-05-21 IL IL156055A patent/IL156055A/en not_active IP Right Cessation
- 2003-05-27 IS IS6829A patent/IS6829A/is unknown
- 2003-05-28 NO NO20032425A patent/NO20032425L/no not_active Application Discontinuation
- 2003-05-29 BG BG107856A patent/BG107856A/xx unknown
2004
- 2004-07-28 US US10/901,845 patent/US6992194B2/en not_active Expired - Fee Related
- 2004-11-19 US US10/994,142 patent/US7144916B2/en not_active Expired - Fee Related
2005
- 2005-07-29 US US11/192,707 patent/US7151183B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/193,112 patent/US7189861B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/193,089 patent/US7256212B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,674 patent/US7456297B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,672 patent/US7161012B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,821 patent/US7342120B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,815 patent/US20060106232A1/en not_active Abandoned
- 2005-10-24 US US11/257,979 patent/US7468444B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,828 patent/US7488750B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,886 patent/US20060100267A1/en not_active Abandoned
- 2005-10-24 US US11/257,808 patent/US20060106231A1/en not_active Abandoned
2007
- 2007-10-23 US US11/977,387 patent/US20080214650A1/en not_active Abandoned
2009
- 2009-03-11 JP JP2009058477A patent/JP2009120624A/ja active Pending

Also Published As

Publication number	Publication date
BR0115892A (pt)	2003-10-28
EP2192112A1 (fr)	2010-06-02
US20050261361A1 (en)	2005-11-24
US20050090542A1 (en)	2005-04-28
US20020183378A1 (en)	2002-12-05
HUP0600538A3 (en)	2010-09-28
YU42803A (sh)	2006-05-25
US7256212B2 (en)	2007-08-14
US20060100446A1 (en)	2006-05-11
AU2002217927A1 (en)	2002-06-11
CZ20031766A3 (cs)	2004-08-18
HUP0600538A2 (en)	2006-09-28
CA2429590C (fr)	2008-06-10
HRP20130545A2 (hr)	2013-11-08
US7189861B2 (en)	2007-03-13
ES2215495T1 (es)	2004-10-16
KR20030059297A (ko)	2003-07-07
US7456297B2 (en)	2008-11-25
NO20032425D0 (no)	2003-05-28
EP1783113A3 (fr)	2007-05-30
CA2625277A1 (fr)	2002-06-06
KR100765871B1 (ko)	2007-10-11
NO20032425L (no)	2003-07-25
CN1489463A (zh)	2004-04-14
US7342120B2 (en)	2008-03-11
EP1363621A4 (fr)	2005-12-28
US20050282885A1 (en)	2005-12-22
ES2437157T3 (es)	2014-01-09
US20060106231A1 (en)	2006-05-18
US20050261360A1 (en)	2005-11-24
SK8062003A3 (en)	2004-07-07
US20060100445A1 (en)	2006-05-11
US20050267198A1 (en)	2005-12-01
WO2002043732A1 (fr)	2002-06-06
EP2194041A1 (fr)	2010-06-09
EP2192112B1 (fr)	2013-08-28
EP1783113A2 (fr)	2007-05-09
US6992194B2 (en)	2006-01-31
US7468444B2 (en)	2008-12-23
US20050004206A1 (en)	2005-01-06
IL156055A (en)	2010-12-30
US7161012B2 (en)	2007-01-09
PL363228A1 (en)	2004-11-15
EP2192113A1 (fr)	2010-06-02
CA2429590A1 (fr)	2002-06-06
CA2689915A1 (fr)	2002-06-06
US20080214650A1 (en)	2008-09-04
US7144916B2 (en)	2006-12-05
TR200400815T3 (tr)	2004-07-21
DE01998348T1 (de)	2004-08-26
JP2004514694A (ja)	2004-05-20
IL156055A0 (en)	2003-12-23
IS6829A (is)	2003-05-27
EP1363621A1 (fr)	2003-11-26
US20060058533A1 (en)	2006-03-16
MXPA03004844A (es)	2005-04-19
US20050261359A1 (en)	2005-11-24
US7151183B2 (en)	2006-12-19
JP2009120624A (ja)	2009-06-04
US20060100267A1 (en)	2006-05-11
US7488750B2 (en)	2009-02-10
US20060106232A1 (en)	2006-05-18
HRP20030523A2 (en)	2005-06-30

Publication	Publication Date	Title
YU42803A (sh)	2006-05-25	Novi kristalni oblici atorvastatin hemi-kalcijuma i postupci za njihovo pripremanje kao i novi postupci za pripremanje drugih oblika
AU2002319814A1 (en)	2003-03-03	Substituted 1h-dihydropyrazoles, their preparation and use
MXPA03011329A (es)	2004-03-19	Antiinfecciosos novedosos.
TNSN07235A1 (en)	2008-11-21	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
MXPA03006093A (es)	2005-02-14	Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
WO2004043918A3 (fr)	2004-07-15	Nouvelles formes cristallines d'atorvastatine hemi-calcium et leurs procedes de preparation ainsi que de nouveaux procedes de preparation d'autres formes
PL372303A1 (en)	2005-07-11	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
MY133969A (en)	2007-11-30	Indoloquinazolinones
MXPA04000889A (es)	2004-06-03	Formas cristalinas vi y vii de atorvastatina calcica.
AU2002353775A1 (en)	2003-03-10	Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
HK1045309A1 (zh)	2002-11-22	取代的哌啶-4-酮的制备
AU7027100A (en)	2001-04-17	Novel compounds
BG106002A (en)	2002-06-28	Process for preparing pesticidal intermediates
MXPA03010498A (es)	2004-05-27	Proceso para la preparacion de imipenem.
GB0108903D0 (en)	2001-05-30	Novel crystalline forms of a factor Xa inhibitor
LT2004018A (en)	2004-09-27	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL148161A0 (en)	2002-09-12	Process for the preparation of 2-cyanopyridines
PL343546A1 (en)	2001-08-27	Processes for preparing intermediates
ZA983231B (en)	1999-10-18	Substituted benzyloxyimino compounds.
MXPA04000623A (es)	2004-04-20	Derivados de tetrahidropiridazina y su uso como pesticidas.
DE60212130D1 (en)	2006-07-20	Carvedilolpolymorph
CA2328832A1 (fr)	1999-10-28	Procedes relatifs a la preparation d'intermediaires utiles dans l'elaboration des pesticides
DE50006244D1 (en)	2004-06-03	Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
MXPA05007696A (es)	2005-09-30	Modificacion cristalina de un complejo de manganeso.
AP2003002912A0 (en)	2002-05-17	Process for the preparation of amorphouse cilastatin sodium